Published in BMC Immunol on October 02, 2006
Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem (2010) 1.52
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
An intein-mediated site-specific click conjugation strategy for improved tumor targeting of nanoparticle systems. Small (2010) 0.97
Designer lipids for drug delivery: from heads to tails. J Control Release (2014) 0.88
Influence of multivalent nitrilotriacetic acid lipid-ligand affinity on the circulation half-life in mice of a liposome-attached His6-protein. Bioconjug Chem (2010) 0.87
Identification of an antibody fragment specific for androgen-dependent prostate cancer cells. BMC Biotechnol (2014) 0.80
Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy. Sci Rep (2017) 0.79
Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. MAbs (2015) 0.78
High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One (2014) 0.78
Ligand-targeted theranostic nanomedicines against cancer. J Control Release (2016) 0.77
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs (2016) 0.75
Antibody-induced internalization of the human respiratory syncytial virus fusion protein. J Virol (2017) 0.75
Phosphorus assay in column chromatography. J Biol Chem (1959) 60.56
Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J (2004) 6.90
By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol (1991) 6.62
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A (2005) 3.78
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J Am Chem Soc (2004) 2.49
Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng (2006) 2.39
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A (1998) 2.32
Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr Opin Chem Biol (2004) 2.05
Oligomerized transferrin receptors are selectively retained by a lumenal sorting signal in a long-lived endocytic recycling compartment. J Cell Biol (1995) 2.02
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol (1997) 1.85
Metal-affinity separations: a new dimension in protein processing. Biotechnology (N Y) (1991) 1.74
Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell (1983) 1.73
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem (2006) 1.71
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res (1992) 1.62
Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol (2000) 1.60
Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry (1990) 1.60
Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res (2002) 1.55
Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol (2001) 1.54
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry (1997) 1.45
Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y) (1993) 1.40
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology (1995) 1.38
Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 1.37
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A (1995) 1.32
A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol (1993) 1.32
Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat (2003) 1.27
Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry (1993) 1.26
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer (1998) 1.25
Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun (1999) 1.23
Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett (1992) 1.19
Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol (1999) 1.18
Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A (1995) 1.18
Remarkably size-regulated cell invasion by artificial viruses. Saccharide-dependent self-aggregation of glycoviruses and its consequences in glycoviral gene delivery. J Am Chem Soc (2003) 1.17
Molecular organization of histidine-tagged biomolecules at self-assembled lipid interfaces using a novel class of chelator lipids. Proc Natl Acad Sci U S A (1995) 1.15
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res (2000) 1.15
The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding. J Biol Chem (1999) 1.14
Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res (1998) 1.10
Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis. J Biol Chem (2003) 1.10
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods (2001) 1.06
Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J Biol Chem (1998) 1.03
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol (2001) 1.00
Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A (2001) 0.98
Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun (1999) 0.94
Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc Natl Acad Sci U S A (1995) 0.93
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res (1996) 0.92
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta (2002) 0.92
Functional immobilization of a DNA-binding protein at a membrane interface via histidine tag and synthetic chelator lipids. Biochemistry (1996) 0.92
Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem (2000) 0.89
Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun (2001) 0.87
Specific interaction and two-dimensional crystallization of histidine tagged yeast RNA polymerase I on nickel-chelating lipids. Biophys J (1998) 0.87
Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett (2002) 0.86
Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells. J Immunol Methods (1999) 0.86
Engrafting costimulator molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol (2000) 0.84
Distribution of endocytosed molecules to intracellular acidic environments correlates with immunotoxin activity. Int J Cancer (1990) 0.81
Interaction of liposomes with cells. Methods Enzymol (1987) 0.80
Selection of human antibody fragments on the basis of stabilization of the variable domain in the presence of target antigens. Biochem Biophys Res Commun (2002) 0.80
An alternating selection strategy for cloning phage display antibodies. J Immunol Methods (1999) 0.78
Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes. Biochim Biophys Acta (2001) 0.77
The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. Semin Cancer Biol (1996) 0.76
Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. Biochemistry (1996) 0.76
Antibody transport and internalization into tumours. Br J Cancer Suppl (1990) 0.76
Cell membrane antigen-antibody complex dissociation by the widely used glycine-HCL method: an unreliable procedure for studying antibody internalization. Immunol Invest (1993) 0.76
Enhanced capture of small histidine-containing polypeptides on membranes in the presence of ZnCl2. Biotechniques (2001) 0.76
A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Int J Cancer (2002) 0.76
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One (2007) 2.28
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Antibodies from phage antibody libraries. J Immunol Methods (2004) 1.75
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res (2005) 1.51
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J Med Microbiol (2003) 1.45
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res (2006) 1.43
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (2005) 1.38
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett (2008) 1.34
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat (2003) 1.27
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol (2002) 1.18
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods (2006) 1.17
Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol (2012) 1.15
Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol (2007) 1.11
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol (2010) 1.10
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol (2002) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm (2005) 1.06
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging (2010) 1.05
Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol (2002) 1.05
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther (2008) 1.04
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res (2005) 1.03
Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics (2006) 1.00
Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va. Biochemistry (2002) 1.00
Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett (2004) 0.99
Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl) (2007) 0.99
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res (2008) 0.99
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog (2005) 0.98
Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem (2007) 0.98
Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol (2010) 0.97
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother (2007) 0.96
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol (2012) 0.96
Specificity of soluble phospholipid binding sites on human factor Xa. Biochemistry (2002) 0.95
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol (2009) 0.95
Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods (2004) 0.94
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res (2009) 0.93
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther (2012) 0.92
Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release (2009) 0.92